We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Accuray's (ARAY) CyberKnife Effective for Relief From TN Pain
Read MoreHide Full Article
Accuray Incorporated (ARAY - Free Report) recently announced favorable long-term follow-up data from a study of patients with trigeminal neuralgia (“TN”). The data indicates that majority of the patients continued to experience pain relief 10 years after receiving image-guided robotic radiosurgery treatments delivered with Accuray’s CyberKnife System.
It is worth mentioning that TN-related pain, which occurs most frequently in people over the age of 50, is more common in women than in men, and can be triggered by the lightest of touches to the face or even a gentle breeze.
The latest favorable data is expected to be a step forward for Accuray to strengthen its radiation therapy business on a global scale.
Significance of the Study Result
TN can impact patients over the course of their lives, thereby making long-term medical care a necessity. Treatment of TN starts with medication to block the pain signals sent to the brain, which gradually might become less effective. Resultantly, some patients may even experience unpleasant side effects over time. Alternative treatments, such as injections, radiofrequency, balloon compression, surgery or radiosurgery may be required for such patients.
Per a medical expert, if the TN-induced debilitating chronic pain is left untreated or is inadequately treated, it can be difficult to perform the most common daily activities like eating and even talking. The expert also stressed that significant studies like this are useful in demonstrating that with treatment options like CyberKnife radiosurgery, long-term pain control without a rigid head frame, surgery or medications can be provided. This is expected to improve patient outcome.
Per management, clinical data continues to highlight the long-lasting benefits provided by CyberKnife radiosurgery. The latest TN-related study emphasizes the importance of CyberKnife radiosurgery when precision and accuracy are essential, and also reflects the positive impact this non-invasive treatment option may have on patients suffering from this severe and challenging-to-treat medical condition.
Industry Prospects
Per a report by Research and Markets, the global TN treatment market was valued at $46.53 million in 2016 and is anticipated to reach $99.17 million by 2025 at a CAGR of 7.6%. Factors like growing prevalence of chronic pain disorders and rising public awareness about the condition are likely to drive the market.
Given the market potential, the latest favorable data are expected to provide a significant boost to Accuray’s business globally.
Notable Developments
Last month, Accuray announced that its CyberKnife S7 System has been used by the CARTI medical care team in Little Rock, AR, to treat the first patients in the state.
In February, the company announced that the National Institute for Health and Care Excellence in the U.K. has endorsed radiosurgery for TN, thereby strengthening the evidence for the company to market its CyberKnife Treatment Delivery System for this indication in the country.
The same month, Accuray announced that Queensland, Australia-based Royal Brisbane and Women's Hospital has selected two Radixact Systems with ClearRT helical fan-beam kVCT imaging and Synchrony artificial intelligence-driven four-dimensional dynamic delivery technology to expand access to potentially life-saving radiotherapy treatments to more patients.
Price Performance
Shares of the company have lost 32.1% in the past year against the industry’s 2.9% growth and the S&P 500's 11.9% rise.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Accuray carries a Zacks Rank #3 (Hold).
A few stocks from the broader medical space that investors can consider are AMN Healthcare Services, Inc. (AMN - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Henry Schein, Inc. (HSIC - Free Report) .
AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN’s earnings surpassed estimates in the trailing four quarters, the average surprise being 20%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare has gained 40.6% against the industry’s 53.9% fall over the past year.
IDEXX, carrying a Zacks Rank #2 (Buy), has an estimated long-term growth rate of 13%. IDXX’s earnings surpassed estimates in the trailing four quarters, the average surprise being 18.6%.
IDEXX has gained 12.7% compared with the industry’s 2.9% growth over the past year.
Henry Schein has an estimated long-term growth rate of 11.8%. HSIC’s earnings surpassed estimates in the trailing four quarters, the average surprise being 25.5%. It currently has a Zacks Rank #2.
Henry Schein has gained 29.5% compared with the industry’s 9.7% growth over the past year.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Accuray's (ARAY) CyberKnife Effective for Relief From TN Pain
Accuray Incorporated (ARAY - Free Report) recently announced favorable long-term follow-up data from a study of patients with trigeminal neuralgia (“TN”). The data indicates that majority of the patients continued to experience pain relief 10 years after receiving image-guided robotic radiosurgery treatments delivered with Accuray’s CyberKnife System.
It is worth mentioning that TN-related pain, which occurs most frequently in people over the age of 50, is more common in women than in men, and can be triggered by the lightest of touches to the face or even a gentle breeze.
The latest favorable data is expected to be a step forward for Accuray to strengthen its radiation therapy business on a global scale.
Significance of the Study Result
TN can impact patients over the course of their lives, thereby making long-term medical care a necessity. Treatment of TN starts with medication to block the pain signals sent to the brain, which gradually might become less effective. Resultantly, some patients may even experience unpleasant side effects over time. Alternative treatments, such as injections, radiofrequency, balloon compression, surgery or radiosurgery may be required for such patients.
Per a medical expert, if the TN-induced debilitating chronic pain is left untreated or is inadequately treated, it can be difficult to perform the most common daily activities like eating and even talking. The expert also stressed that significant studies like this are useful in demonstrating that with treatment options like CyberKnife radiosurgery, long-term pain control without a rigid head frame, surgery or medications can be provided. This is expected to improve patient outcome.
Per management, clinical data continues to highlight the long-lasting benefits provided by CyberKnife radiosurgery. The latest TN-related study emphasizes the importance of CyberKnife radiosurgery when precision and accuracy are essential, and also reflects the positive impact this non-invasive treatment option may have on patients suffering from this severe and challenging-to-treat medical condition.
Industry Prospects
Per a report by Research and Markets, the global TN treatment market was valued at $46.53 million in 2016 and is anticipated to reach $99.17 million by 2025 at a CAGR of 7.6%. Factors like growing prevalence of chronic pain disorders and rising public awareness about the condition are likely to drive the market.
Given the market potential, the latest favorable data are expected to provide a significant boost to Accuray’s business globally.
Notable Developments
Last month, Accuray announced that its CyberKnife S7 System has been used by the CARTI medical care team in Little Rock, AR, to treat the first patients in the state.
In February, the company announced that the National Institute for Health and Care Excellence in the U.K. has endorsed radiosurgery for TN, thereby strengthening the evidence for the company to market its CyberKnife Treatment Delivery System for this indication in the country.
The same month, Accuray announced that Queensland, Australia-based Royal Brisbane and Women's Hospital has selected two Radixact Systems with ClearRT helical fan-beam kVCT imaging and Synchrony artificial intelligence-driven four-dimensional dynamic delivery technology to expand access to potentially life-saving radiotherapy treatments to more patients.
Price Performance
Shares of the company have lost 32.1% in the past year against the industry’s 2.9% growth and the S&P 500's 11.9% rise.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Accuray carries a Zacks Rank #3 (Hold).
A few stocks from the broader medical space that investors can consider are AMN Healthcare Services, Inc. (AMN - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Henry Schein, Inc. (HSIC - Free Report) .
AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN’s earnings surpassed estimates in the trailing four quarters, the average surprise being 20%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare has gained 40.6% against the industry’s 53.9% fall over the past year.
IDEXX, carrying a Zacks Rank #2 (Buy), has an estimated long-term growth rate of 13%. IDXX’s earnings surpassed estimates in the trailing four quarters, the average surprise being 18.6%.
IDEXX has gained 12.7% compared with the industry’s 2.9% growth over the past year.
Henry Schein has an estimated long-term growth rate of 11.8%. HSIC’s earnings surpassed estimates in the trailing four quarters, the average surprise being 25.5%. It currently has a Zacks Rank #2.
Henry Schein has gained 29.5% compared with the industry’s 9.7% growth over the past year.